NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone (OTCQB: NRXBF) announced it received C$3,185,994.43 in gross proceeds from accelerated warrant exercises completed after acceleration notices issued on October 8, 2025.
The company reported C$1,207,418.88 from 2,515,456 September 2023 warrants at C$0.48 each and C$1,978,575.55 from 5,653,073 January 2024 warrants at C$0.35 each. Proceeds will be used for general corporate purposes and working capital to support development of its exosome-based therapeutic platform, including ExoPTEN. NurExone also received finalist recognition at Falling Walls (Berlin) and Prix Galien Bridges (Stockholm, December 5, 2025).
NurExone (OTCQB: NRXBF) was accepted into the ARMI BioFab Startup Lab under the federally supported BioFabUSA program on Nov 3, 2025. The program aims to accelerate translation of regenerative innovations into scalable, commercially viable manufacturing.
The company said participation could support plans by its U.S. subsidiary Exo-Top to develop a GMP-compliant facility for naive exosome production and may enhance its value proposition to strategic partners and shareholders.
NurExone (OTCQB: NRXBF) announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, will present at the Precision EV Forum 2025 in Cambridge, UK on October 27–28, 2025. Dr. Sarel will speak on October 28 about regulatory challenges in the clinical development of ExoPTEN: MSC EVs loaded with PTEN-siRNA and will join a panel on regulatory pathways for exosome therapeutics.
The invitation highlights international interest in NurExone’s lead program ExoPTEN, which has Orphan Drug Designation for acute spinal cord injury and has shown nerve-function restoration and reduced inflammation in preclinical models for spinal cord and optic nerve damage.
NurExone (OTCQB: NRXBF) reported preclinical data showing its lead candidate ExoPTEN produced a reproducible, dose-dependent recovery of visual function in an optic nerve crush (ONC) glaucoma model.
Higher ExoPTEN doses restored scotopic threshold response (STR) amplitudes to levels comparable to uninjured eyes. The study used low (4E+8 particles) and high (4E+9 particles) extrachoroidal doses given twice and measured STR by ERG; responses >5µV were considered detectable.
The company also accelerated expiry of September 2023 and January 2024 warrants, setting a new expiry of 5:00 p.m. (Calgary) on Nov 7, 2025, and noted potential gross proceeds of approximately C$3.2 million if all warrants are exercised. POSITIVE Communications agreement extended to July 10, 2026 with added monthly expense reimbursement.
NurExone Biologic (OTCQB: NRXBF) has announced plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana through its subsidiary Exo-Top Inc. The company has secured an incentive offer of up to $255,000 for this expansion.
The planned GMP-compliant facility will serve as Exo-Top's U.S. manufacturing base, producing exosomes for both NurExone's therapeutic pipeline and business-to-business opportunities in regenerative aesthetics. The expansion aligns with Indiana's robust life sciences sector, which generates over $99 billion in annual economic output and has attracted more than $1.5 billion in venture investments since 2019.
This strategic move supports NurExone's progress toward first-in-human clinical trials of ExoPTEN and its plans to uplist to a major U.S. stock exchange.
NurExone Biologic (OTCQB: NRXBF), a biopharmaceutical company focused on exosome-based regenerative therapies, announced several corporate updates. The company received a patent grant in Israel for "Production of Extracellular Vesicles from Stem Cells", complementing their recent U.S. patent allowance.
The company completed a non-brokered private placement raising C$632,655.68 through the issuance of 930,376 units at C$0.68 per unit. Each unit includes one common share and a half warrant exercisable at C$0.88 for 36 months. The proceeds will support preclinical pipeline and U.S. manufacturing initiatives.
Additionally, NurExone announced upcoming presentations at two major U.S. conferences: the 7th Annual Exosome-Based Therapeutic Development Summit and the Bioprocess International Conference in Boston, where company executives will showcase their ExoTherapy technology.
NurExone Biologic (OTCQB: NRXBF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its proprietary exosome manufacturing process. The patent covers the company's 3D scaffold and shear-stress based bioreactor system for producing stem cell-derived exosomes.
This milestone, combined with the company's GMP-grade Master Cell Bank acquisition in December 2024, strengthens NurExone's supply chain readiness. The technology, developed at the Technion, enables scalable and reproducible exosome production for regenerative therapies. The patent is part of a broader international patent family and is exclusively licensed worldwide to NurExone from the Technion Research and Development Foundation.
NurExone Biologic (OTCQB: NRXBF), a preclinical-stage biotech company developing exosome therapies for central nervous system injuries, reported Q2 2025 financial results and corporate updates. The company raised C$2.3 million through a private placement in April 2025. Key financial metrics show a net loss of US$1.85 million, with R&D expenses of US$0.70 million and G&A expenses of US$1.13 million.
The company achieved significant milestones including: plans to initiate Phase 1/2a trial of ExoPTEN for acute spinal cord injury in 2026, new manufacturing process validation data supporting scalability, and acceptance into ARMI's HealthTech Hub Accelerator. NurExone is advancing its GMP-readiness through Master Cell Bank-based manufacturing and progressing with U.S. tech transfer planning and IND-enabling activities.
NurExone Biologic (OTCQB: NRXBF) has reported promising preclinical imaging results for its ExoPTEN treatment in spinal cord injury repair. MRI-DTI analysis revealed that ExoPTEN-treated animals showed improved structural integrity and tissue organization in injured spinal cords compared to untreated controls.
The imaging data complements previous functional studies where 100% of animals in a higher-dose group regained motor function. The analysis demonstrated higher Fractional Anisotropy values and lower Mean Diffusivity values near injury sites, indicating better structural preservation.
Additionally, the company has closed a private placement of C$0.78 million, issuing 1,258,072 units at C$0.62 per unit. Each unit includes one common share and a half warrant exercisable at C$0.80 for 36 months.
NurExone Biologic (OTCQB: NRXBF) announced that an independent study by TAmiRNA laboratory revealed their exosomes significantly outperformed commercial industry standards in key healing capabilities. The company's exosomes demonstrated approximately 1.8x higher neurological potential, 2x higher tissue-regeneration and wound-healing signals, and nearly double the anti-inflammatory activity compared to benchmark products.
The analysis, conducted on exosomes produced from NurExone's proprietary master cell bank, validates the company's core technology for therapeutic nerve repair and aesthetic applications. The exosomes will be manufactured by NurExone's U.S. subsidiary, ExoTOP Inc., using their patent-pending 3D production process.